MedTrace Logo

CUE-102 in Recurrent Glioblastoma

NCT06917885 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).

The name of the study drug involved in this study is:

-CUE-102 (a type of fusion protein)

Conditions

Interventions

BIOLOGICAL

CUE-102

A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

  • Cue Biopharma

    collaborator INDUSTRY

  • David Reardon, MD

    lead OTHER

Principal Investigators

  • David Reardon, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917885 on ClinicalTrials.gov